Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | mitogen-activated protein kinase 1 | Starlite/ChEMBL | No references |
Homo sapiens | ataxin 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Trypanosoma brucei | mitogen-activated protein kinase 5 | mitogen-activated protein kinase 1 | 360 aa | 361 aa | 33.2 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0062 | 0.7195 | 1 |
Trypanosoma brucei | mitogen activated protein kinase 4, putative | 0.0062 | 0.7195 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.7195 | 0.5 |
Loa Loa (eye worm) | RNA binding protein | 0.0074 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.7195 | 0.5 |
Leishmania major | mitogen activated protein kinase 4, putative;with=GeneDB:LmxM19.1440 | 0.0062 | 0.7195 | 1 |
Brugia malayi | TAR-binding protein | 0.0074 | 1 | 1 |
Toxoplasma gondii | CMGC kinase, MAPK family (ERK) MAPK-1 | 0.0062 | 0.7195 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 1 | 1 |
Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.0074 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.7195 | 0.5 |
Plasmodium vivax | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Echinococcus granulosus | tar DNA binding protein | 0.0074 | 1 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 2, putative | 0.0062 | 0.7195 | 1 |
Leishmania major | mitogen activated protein kinase, putative,map kinase, putative | 0.0062 | 0.7195 | 1 |
Trypanosoma cruzi | mitogen activated protein kinase 4, putative | 0.0062 | 0.7195 | 1 |
Brugia malayi | RNA recognition motif domain containing protein | 0.0074 | 1 | 1 |
Plasmodium falciparum | ataxin-2 like protein, putative | 0.003 | 0 | 0.5 |
Brugia malayi | MAP kinase sur-1 | 0.0062 | 0.7195 | 0.7195 |
Trypanosoma cruzi | mitogen-activated protein kinase 11, putative | 0.0062 | 0.7195 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 1 | 1 |
Trichomonas vaginalis | CMGC family protein kinase | 0.0062 | 0.7195 | 0.5 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 1 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 1 | 1 |
Trypanosoma brucei | protein kinase, putative | 0.0062 | 0.7195 | 1 |
Schistosoma mansoni | tar DNA-binding protein | 0.0074 | 1 | 1 |
Giardia lamblia | Kinase, CMGC MAPK | 0.0062 | 0.7195 | 0.5 |
Echinococcus multilocularis | tar DNA binding protein | 0.0074 | 1 | 1 |
Loa Loa (eye worm) | CMGC/MAPK/ERK1 protein kinase | 0.0062 | 0.7195 | 0.7195 |
Loa Loa (eye worm) | TAR-binding protein | 0.0074 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | = 8.9125 um | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF. (Class of assay: confirmatory) [Related pubchem assays: 995 ] | ChEMBL. | No reference |
Potency (functional) | 11.9173 uM | PubChem BioAssay. qHTS for Inhibitors of ATXN expression. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 39.8107 uM | PubChem BioAssay. qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1). (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of Polymerase Iota. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588623] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.